v3.26.1
Notes Receivable (Details) - USD ($)
3 Months Ended 12 Months Ended
Jun. 26, 2025
Apr. 22, 2025
Apr. 08, 2025
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Notes Receivable [Line Items]            
Number of warrant to purchase (in Shares)       698,798    
Fair value of warrant       $ 11,800,798 $ (13,145)  
Interest income       280 $ 288  
Fair value of note receivables       107,805    
Fair value of Evofem notes       $ 4,007,664   $ 3,899,859
Evofem April Note [Member]            
Notes Receivable [Line Items]            
Percentage of evofem stock       9.99%    
Accrued interest       $ 0    
Recognized gain           204,278
Outstanding principal balance       2,307,692    
Unamortized debt discount       2,495,633    
Interest income       0    
Fair value of note receivables       67,326    
Evofem April Note [Member] | Warrant [Member]            
Notes Receivable [Line Items]            
Original issuance discount       4,367,212    
Fair value of note receivable       1,938,905    
Notes, paid, value       2,428,307    
Outstanding principal balance       2,307,692    
Accrued interest       $ 136,923    
Evofem June Note [Member]            
Notes Receivable [Line Items]            
Percentage of evofem stock       9.99%    
Original issuance discount       $ 2,667,701    
Notes, paid, value       1,471,552    
Outstanding principal balance       1,423,077    
Accrued interest       0    
Recognized gain           123,793
Outstanding principal balance           1,423,077
Unamortized debt discount           $ 1,512,031
Interest income       0    
Fair value of note receivables       18,110    
Warrants issued       1,196,149    
Convertible Notes Receivable [Member]            
Notes Receivable [Line Items]            
Accrued interest       59,453    
Evofem Notes [Member]            
Notes Receivable [Line Items]            
Fair value of Evofem notes       $ 4,007,664    
Evofem April Purchase Agreement [Member]            
Notes Receivable [Line Items]            
Number of warrant to purchase (in Shares)     149,850,150      
Common stock purchase price     $ 1,500,000      
Exercise price per share (in Dollars per share)     $ 0.0154      
Percentage of evofem stock     9.99%      
Fair value of warrant     $ 235,389      
Warrants exercisable     5 years      
Fund payment   $ 1,500,000        
Evofem April Purchase Agreement [Member] | Senior subordinated convertible note [Member]            
Notes Receivable [Line Items]            
Principal amount     $ 2,307,692      
Evofem June Purchase Agreement [Member]            
Notes Receivable [Line Items]            
Number of warrant to purchase (in Shares) 92,407,592          
Common stock purchase price $ 925,000          
Exercise price per share (in Dollars per share) $ 0.0154          
Percentage of evofem stock 9.99%          
Fair value of warrant $ 92,682          
Warrants exercisable 5 years          
Fund payment $ 925,000          
Evofem June Purchase Agreement [Member] | Senior subordinated convertible note [Member]            
Notes Receivable [Line Items]            
Principal amount $ 1,423,077          
Minimum [Member] | Evofem April Note [Member]            
Notes Receivable [Line Items]            
Interest rate per annum       8.00%    
Minimum [Member] | Evofem June Note [Member]            
Notes Receivable [Line Items]            
Interest rate per annum       8.00%    
Maximum [Member] | Evofem April Note [Member]            
Notes Receivable [Line Items]            
Interest rate per annum       12.00%    
Maximum [Member] | Evofem June Note [Member]            
Notes Receivable [Line Items]            
Interest rate per annum       12.00%    
Common Stock [Member] | Evofem April Note [Member]            
Notes Receivable [Line Items]            
Conversion price per share (in Dollars per share)       $ 0.0154    
Common Stock [Member] | Evofem June Note [Member]            
Notes Receivable [Line Items]            
Conversion price per share (in Dollars per share)       $ 0.0154